Growth Hormone Peptides

AOD-9604: synthetic hGH fragment 177-191 peptide (≥98% purity). β3-adrenergic receptor modulator for lipolysis research. Laboratory use only. Not for human consumption.

• 83-AA Recombinant IGF-1 Analog: Long R3 modifications confer ~3× potency vs. native IGF-1 and 20-30h half-life, ≥98% purity
• Reduced IGFBP Binding / Dual Signaling: Bypasses IGFBP sequestration; activates IGF-1R via PI3K/Akt/mTOR and MAPK/ERK cascades
• Cell Culture & Preclinical Research: Replaces insulin at 200-fold lower concentrations; validated in 22+ peer-reviewed publications

Ipamorelin pentapeptide - selective GHS-R1a agonist with unique hormonal selectivity profile. ≥98% purity, research-grade, EC₅₀ = 1.3 nmol/L. Laboratory use only.

• GHRH Analog with DAC: 30-amino acid peptide with albumin-binding technology, ≥98% purity
• Extended Half-Life: 5.8-8.1 day biological half-life via maleimide-albumin conjugation
• GH/IGF-1 Axis Research: Sustained 2-10 fold GH and 1.5-3 fold IGF-1 elevation studies

• Compound: 29-amino acid synthetic GHRH(1-29)-NH₂; biologically active N-terminal fragment of human growth hormone-releasing hormone
• Mechanism: Binds GHRH-R on pituitary somatotrophs; activates Gs-cAMP-PKA-CREB signaling cascade for physiological pulsatile GH release under somatostatin feedback regulation
• Validation: Authorized 1990 (diagnostic) and 1997 (pediatric GH deficiency); extensively characterized in peer-reviewed endocrinology, neuroendocrinology, and oncology research

• Synthetic GHRH Analog: 44-amino acid polypeptide with N-terminal trans-3-hexenoic acid modification; enhanced DPP-IV resistance extends half-life to 26–38 min vs. minutes for native GHRH; 150+ PubMed publications
• Physiological GH Axis Modulation: Selective GHRH-R agonist preserving pulsatile GH secretion patterns and IGF-1 feedback regulation; studied in clinical trials for metabolic effects in HIV-associated lipodystrophy
• Regulatory Status: Tesamorelin (Egrifta) authorized 2010 for HIV-associated lipodystrophy; Egrifta WR (F8 formulation) authorized March 2025 with reconstitution updates; ongoing research in neurocognitive and hepatic biology